PEGS Europe Tablet Banner

Cambridge Healthtech Institute’s 7th Annual
Optimisation & Developability

Selecting and Enhancing the Best Molecule to Move Forward

31 October – 1 November 2016 | EPIC SANA Lisboa Hotel | Lisboa PORTUGAL

In today’s competitive world of myriad biologics formats and the ever-increasing regulatory demands, it is imperative for companies to come up with the best and fastest way to assess a molecule’s developability and manufacturability, optimise candidate molecule’s properties for half-life extension, solubility and stability, and engineer molecules to improve affinity, specificity and efficacy while reducing aggregation. These tools and strategies not only contribute to streamlining efficacy-toxicology evaluation, but also allows for pharmacologically effective, and developable candidates to reach the clinic and successfully to the market.

The 7th Annual Optimisation & Developability conference will bring together these cutting-edge technologies and creative approaches that companies are employing to evaluate, select and optimise the candidates to move forward.

Preliminary Agenda


Immunotherapy Approaches in the Clinic

Renier J. Brentjens, M.D., Ph.D., Director, Cellular Therapeutics, Memorial Sloan-Kettering Cancer Center

Biotherapeutic Programs that Re-Direct Cytotoxic Lymphocytes to Cancer Cells

Paul Adam, Ph.D., Executive Director, Immune Modulation and Biotherapeutics Discovery, Boehringer Ingelheim


New Capillary Electrophoretic Systems for the Affinity Assessment of Protein Mixture Components

Gerhardus de Jong, Ph.D., Professor, Pharmaceutical Sciences, Utrecht University

Novel Approaches for Rapid Degradation Hotspot Profiling of Biotherapeutic Candidates

Christian Graf, Ph.D., Principal Scientist, Biologics Technical Development and Manufacturing, NBE-IBP, Novartis Pharma AG

Developability Assessment of Complex Biologics

Laurent Lariviere, Ph.D., Principal Scientist, Large Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Penzberg, Roche Diagnostics GmbH


Analytical Strategies to Guide Candidate Selection through Optimization and Developability Assessment

Johnson Varghese, Ph.D., Head, Analytical Development, Shire

Assessing Developability-Related Issues with Computational and Experimental Methods

Daniel Seeliger, Ph.D., Research Scientist, Discovery Research, Boehringer-Ingelheim Pharma

Fingerprinting Antibody Epitopes: Identifying Even Minor Variations for QC and IP

Michael Szardenings, Dr.rer.nat., Group Leader, Immunology, Ligand Development, Fraunhofer Institute for Cell Therapy and Immunology

Attribute Tailored Bioprocess Development to Allow ‘Designed In’ Appropriate Product Quality

Karolina Les, Ph.D., Scientist I, Purification Process Sciences, Biopharmaceutical Development, MedImmune


Building a Pipeline in Immuno-Oncology: Bispecific Antibodies from Engineering to Optimized In-House Phase I Manufacturing

Stanislas Blein, Ph.D., Head, Antibody Engineering, Glenmark Pharmaceuticals

Preclinical Tools in Formulation Optimization to Improve Biological Performance of Antibodies

Sabine Eichling, Ph.D. Student, NBE Formulation Sciences, Abbvie Deutschland GmbH & Co. KG, University of Heidelberg

Characterizing and Optimizing Glycostructures by Targeted Cell Engineering Cell-Based Glycan Display

Claus Kristensen, Ph.D., Assistant Professor, Copenhagen Center for Glycomics, University of Copenhagen

Mitigating Acid Induced Aggregation during Protein-A Affinity Chromatography

John Kawooya, Ph.D., Director, Biologics Optimization, Amgen

For more details on the conference, please contact:
Mimi Langley
Senior Conference Director
Cambridge Healthtech Institute
T: +1 781.972.5439

For exhibit & sponsorship opportunities, please contact:

Companies A-K
Jason Gerardi
Business Development Manager
(+1) 781-972-5452

Companies L-Z
Carol Dinerstein
Director, Business Development
(+1) 781-972-5471